Castle Biosciences Q1 revenue up 57% to $42M; reaffirms FY 2023 guidance $170-180M

CASTLE BIOSCIENCES INC

2023-Q1 EPS reported -$1.10 revenue$42,037,000

Delivered 14,916 total test reports (+73% YoY); DecisionDx-Melanoma 7,583 (+26%), DecisionDx-SCC 2,411 (+111%).
Revenue $42.0M (+57% YoY); adjusted revenue $43.4M (+65%); net loss ($29.2M) vs ($24.6M) prior year.
Gross margin 70.5% (adjusted 76.5%); cash & marketable securities $232.1M as of March 31, 2023.
Reaffirms full-year 2023 revenue guidance of $170-180M; Q1 cash use includes $17.7M non-recurring bonus/benefit payments.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CASTLE BIOSCIENCES INC reported the first quarter ended March 31, 2023 results: revenue $42.0 million, net income $(29.2) million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $42.0 million
Net income: $(29.2) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Castle Biosciences Reports First Quarter 2023 Results Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180 million

View on SEC.gov

Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-23-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.